Shares declined 2.1% following Certara’s Q2 report as investors appeared unimpressed by modest revenue growth, persistent service revenue weakness, and cautious full-year guidance despite ongoing transformation efforts.
- Revenue grew 1% in Q2, with software up 4% but services down 3%, reflecting ongoing challenges in the services segment.
- Trailing 12-month software bookings rose 7% (excluding Chemaxon), showing some momentum improvement from prior periods.
- Services bookings remained sluggish with a 1.07 book-to-bill ratio, partly impacted by divestiture of regulatory and medical writing businesses.
- The company reaffirmed full-year revenue growth guidance of 0% to 4%, signaling a cautious outlook.
- Cost reduction efforts, including a 5% workforce reduction, are expected to generate $13 million in run-rate savings to support innovation investments.
Community Discussion